



NEWS RELEASE

Dec. 3, 2018  
TMS Co., Ltd.

**TMS appoints pharmaceutical executive Steve Engen as new Board member**

Fuchu-shi, Tokyo, Dec 3, 2018

TMS Co., Ltd. (Fuchu-shi, Tokyo, JAPAN / CEO Takuro Wakabayashi, “TMS”) today announced that Steve Engen has been appointed as an independent director to the company’s Board of Directors. Mr. Engen is an accomplished leader and entrepreneur with over 20 years of experience in the global pharmaceutical and biotechnology industries.

“We are extremely pleased to welcome Steve Engen as a new Board member,” said Takuro Wakabayashi, CEO of TMS Co., Ltd. “Steve’s extensive leadership experience in both global companies and local settings is a great addition to our Board as we continue to build innovative pipeline that we intend to contribute global health.”

Mr. Engen is currently CEO of Renegen K.K. as well as Co-Founder of Loncar China Biopharma Index (LCHINA). Previously he served as Managing Director and Head of Asia at Locust Walk, Representative Director of Shire Japan, President & CEO of Solasia Pharma K.K. (TSE 4597), and President & Representative Director of Mundipharma Japan.

About TMS Co., Ltd.

TMS Co., Ltd. is a privately-held, clinical stage biotechnology company based in Fuchu-shi, Tokyo. The company was founded in 2005 to develop therapeutics based on novel discoveries to modulate fibrinolytic system, identified by a team of scientists at Tokyo University of Agriculture and Technology (TUAT), led by Dr. Keiji Hasumi, Professor of the university and Chief Scientist of TMS.

CONTACT

Takuro Wakabayashi, President & Representative Director

+81-42-306-5078